Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Résultat
de votre recherche par promoteur : Wyeth
Femme et Homme Max 99 ans
Wyeth Research Division of Wyeth Pharmaceuticals Inc
MAJ Il y a 4 ans
A Phase 3, Open-label, Single-Arm Trial to Evaluate the Safety, Tolerability, and Immunogenicity of 13-valent Pneumococcal Conjugate Vaccine in Children With Sickle Cell Disease Previously Immunized With 23-valent Pneumococcal Polysaccharide Vaccine
To evaluate the immune response 1 month after 2 doses of 13vPnC given 6 months apart compared to 1 month after 1 dose of 13vPnC as measured by fold rise in serotype specific IgG geometric mean concent...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Wyeth Research Division of Wyeth Pharmaceuticals Inc., Clinical Reserach and Development
MAJ Il y a 4 ans
A 6-MONTH, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, SAFETY, TOLERABILITY, AND EFFICACY STUDY OF 3 DOSES OF LECOZOTAN SRA-333 SR IN OUTPATIENTS WITH MILD TO MODERATE ALZHEIMER S DISEASE TREATED WITH A CHOLINESTERASE INHIBITOR
The primary objective is to determine the safety, tolerability, and efficacy of three doses of lecozotan SR 2, 5, 10 mg in combination with a cholinesterase inhibitor in patients with mild to modera...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Wyeth Research Division of Wyeth Pharmaceuticals Inc
MAJ Il y a 4 ans
A Phase 3 Randomized, Open-Label Study of Bosutinib Versus Imatinib in Subjects With Newly Diagnosed Chronic Phase Philadelphia Chromosome Positive Chronic Myelogenous Leukemia
Compare the rate of complete cytogenetic response (CCyR) at one year in chronic phase subjects receiving bosutinib alone versus chronic phase subjects receiving imatinib alone.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Wyeth Research Division of Wyeth Pharmaceuticals Inc
MAJ Il y a 4 ans
A Phase 1 / 2 Study of HKI-272 in combination With Paclitaxel in Subjects With Solid Tumors and Breast Cancer
Part 1: The primary objectives of part 1 are to assess the safety and tolerability, and to define the MTD of HKI-272 in combination with paclitaxel in subjects with advanced solid tumors Part 2: The p...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Wyeth Pharmaceuticals France, Wyeth Research Division
MAJ Il y a 4 ans
An open-label, multicentre, supplementary and extension study of Etanercept in subjects with Ankylosing Spondylitis (AS)
To evaluate the health care resource utilization and work status in patients with ankylosing spondylitis by comparing study evaluations with the baseline evaluations in the ASCEND 0881A3-402-WW Study.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme Max 99 ans
Wyeth Research Division of Wyeth Pharmaceuticals Inc
MAJ Il y a 4 ans
A DOUBLE-BLIND, RANDOMIZED, PLACEBO-AND ACTIVE-CONTROLLED EFFICACY AND SAFETY STUDY OF THE EFFECTS OF BAZEDOXIFENE/CONJUGATED ESTROGENS COMBINATIONS ON ENDOMETRIAL HYPERPLASIA AND PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN
Primary Safety Objective: To confirm the endometrial safety of BZA 20 mg/CE 0.45 mg and BZA 20 mg/CE 0.625 mg based on an endometrial hyperplasia incidence of less than 1% at year 1. Primary Efficacy...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Wyeth Research Division of Wyeth Pharmaceuticals Inc
MAJ Il y a 4 ans
A Randomized, Open-Label Study to Compare the Safety and Efficacy of Conversion From a Calcineurin Inhibitor to Sirolimus Versus Continued Use of a Calcineurin Inhibitor in Cardiac Transplant Recipients With Mild to Moderate Renal Insufficiency
To demonstrate the superiority of converting from CNI therapy to sirolimus therapy to continuing CNI therapy with respect to renal function in cardiac transplant recipients with mild to moderate renal...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Wyeth Research Division of Wyeth Pharmaceuticals Inc, Clinical Research and Development
MAJ Il y a 4 ans
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, TREATMENT-WITHDRAWAL STUDY OF THE EFFICACY AND SAFETY OF PANTOPRAZOLE SODIUM ENTERIC-COATED GRANULES IN INFANTS (1 THROUGH 11 MONTHS) WITH SYMPTOMATIC GERD
To assess the efficacy of treatment with pantoprazole granules administered as a suspension in pediatric patients 1 through 11 months of age. The difference in withdrawal rates will compared between t...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Wyeth Pharmaceuticals, Inc., acting through Wyeth Research, a Pfizer Company
MAJ Il y a 4 ans
A Multicenter, Double-Blind, Placebo-Controlled, Randomized Withdrawal, Parallel Group Study to Evaluate the Efficacy and Safety of 50 mg/day of DVS SR in Adult Outpatients With Major Depressive Disorder
The primary objective is to compare the long-term efficacy and safety of treatment with DVS SR 50 mg/day versus placebo in MDD subjects stabilized on DVS SR, using a randomized withdrawal design. Thi...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Wyeth Research Division of Wyeth Pharmaceuticals Inc
MAJ Il y a 4 ans
A Phase 3, Randomized, Active-Controlled, Double-Blind, Trial Evaluating the Safety, Tolerability and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Pediatric Vaccinations in Spain. - Estudio fase III, randomizado, controlado, doble ciego para evaluar la seguridad, tolerabilidad e inmunogenicidad de la Vacuna Neumocócica Conjugada 13-valente en niños sanos administrada según calendario vacunal en España
Primary objectives· - To demonstrate that the immune response induced by Meningitec given with 13vPnC is noninferior to the immune response induced by Meningitec given with 7vPnC when measured 1 month...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Précédent
1
2
3
4
5
6
7
8
9
10
Suivant